Shihan Zhou
Overview
Explore the profile of Shihan Zhou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
19
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liang L, Mi Y, Zhou S, Yang A, Wei C, Dai E
Front Pharmacol
. 2024 Dec;
15:1403227.
PMID: 39687302
Renal fibrosis (RF) is a pathological process characterized by the excessive accumulation of extracellular matrix (ECM), which triggers a repair cascade in response to stimuli and pathogenic factors, leading to...
2.
Liu J, He M, Jiang M, Zhou S, Zhang M, Li Y, et al.
BMC Cancer
. 2024 Oct;
24(1):1290.
PMID: 39425028
Background: Exploration of novel combination mode of pyrotinib and chemotherapy for heavily pretreated HER2-positive metastatic breast cancer (MBC) and how to balance survival benefits and compliance are still urgent problems...
3.
Zhao Q, Jiang M, Liu J, Zhang M, He M, Zhou S, et al.
Cancer Biol Med
. 2024 Sep;
21(10).
PMID: 39267478
Objective: CDK4/6 inhibitors (CDK4/6is) in combination with endocrine therapy have secured a central role in the treatment of hormone receptor (HR)-positive advanced breast cancer (ABC) and have transformed the therapeutic...
4.
Jiang M, Liu J, He M, Zhang M, Zhou S, Chen S, et al.
Ther Adv Med Oncol
. 2024 Sep;
16:17588359241275422.
PMID: 39257649
Background: Inetetamab is a novel antibody targeting human epidermal growth factor receptor 2 (HER2) developed in China. Due to its optimized antibody-dependent cell-mediated cytotoxicity effect compared with trastuzumab, it has...
5.
Di D, Zhang C, Sun S, Pei K, Gu R, Sun Y, et al.
Heliyon
. 2024 Aug;
10(14):e34823.
PMID: 39149067
Aim: This research examined the possible therapeutic effects of YCD in alleviating PD a systematic approach with network pharmacology and experimental validation, aiming at providing a new understanding of traditional...
6.
Jiang M, Chai Y, Liu J, He M, Wang Y, Yang X, et al.
BMC Cancer
. 2024 Jul;
24(1):877.
PMID: 39039516
Background: Inetetamab is the first domestically developed innovative anti-HER2 monoclonal antibody in China, proven effective and safe in HER2-positive advanced breast cancer. However, its efficacy and safety in neoadjuvant treatment...
7.
Feng X, Zhou S, Liu J, Wu J, Wang J, Zhang W, et al.
J Colloid Interface Sci
. 2024 Jun;
672:401-414.
PMID: 38850865
Crafting an inorganic semiconductor heterojunction with defect engineering and morphology modulation is a strategic approach to produce clean energy by the highly efficient light-driven splitting of water. In this paper,...
8.
Lu W, Zhou S, Ma X, Xu N, Liu D, Zhang K, et al.
Microbiol Spectr
. 2023 Dec;
12(2):e0254223.
PMID: 38149860
This study investigated resistance genes corresponding to the fosfomycin resistance phenotype in clinical isolate W986, as well as characterizing the enzymatic activity of FosA11 and the genetic environment. Antimicrobial susceptibility...
9.
Sun Y, Zhang H, Liu R, Huang R, Zhang X, Zhou S, et al.
J Ethnopharmacol
. 2023 Sep;
319(Pt 2):117214.
PMID: 37739108
Ethnopharmacological Relevanc: Pyrolae herba (PH), a kind of Chinese herb, has been identified to have an anti-inflammatory effect, while the potential for treating cognitive impairment (CI), as well as the...
10.
Liu J, Zhou S, Wang Y, Liu J, Sun S, Sun Y, et al.
J Ethnopharmacol
. 2023 May;
314:116604.
PMID: 37178985
Ethnopharmacological Relevance: Treating cognitive impairment is a challenging and necessary research topic. ZeXieYin Formula (ZXYF), is a traditional herbal formula documented in the book of HuangDiNeiJing. Our previous studies demonstrated...